Table of Contents

• Clinical trial overview
• Studies in chronic graft-versus-host disease
• Study in idiopathic pulmonary fibrosis
• Trial designs and comparison groups
• Main outcomes being measured
• Who may be able to participate

Clinical trial overview

The trial data show that Axatilimab is being studied in people with chronic graft-versus-host disease and idiopathic pulmonary fibrosis.^{[1][2][3][4][5][6]} These studies are designed to look at how well the treatment works, along with safety and tolerability in some trials.^[2][5] The research includes both Phase 2 and Phase 3 studies.^{[1][2][3][4][5][6]}

Studies in chronic graft-versus-host disease

Most of the trials are in people with chronic graft-versus-host disease (cGVHD), a long-term condition that can happen after stem cell transplant.^{[1][2][3][4][6]} One Phase 3 study compares Axatilimab with best available therapy in participants who have already had at least 2 prior lines of systemic therapy, meaning at least 2 earlier body-wide treatments.^[1] Its main goal is to compare efficacy, using response at 6 months as the key measure.^[1]

Another Phase 2 study looks at Axatilimab in combination with ruxolitinib in people with newly diagnosed cGVHD.^[2] This study is randomized and multicenter, which means participants are assigned to groups by chance and the trial is run at more than one site.^[2] The study aims to see the early benefit of the combination and how much Axatilimab adds to the treatment effect.^[2]

A different Phase 3 study tests Axatilimab plus corticosteroids as the first treatment for moderate or severe cGVHD.^[3] It compares Axatilimab with placebo, so some participants receive an inactive treatment for comparison.^[3] The trial measures event-free survival, which is the time before a major study event happens, such as new treatment, death, or treatment failure.^[3]

One Phase 2 study tests 3 different Axatilimab dose schedules in people with cGVHD after failure of at least 2 prior lines of therapy.^[4] The study summary says it is looking at the overall response rate in the first 6 cycles.^[4] Another Phase 2 study is planned for pediatric participants with cGVHD after at least 2 prior lines of systemic therapy, and it compares Axatilimab with best available therapy.^[6]

Study in idiopathic pulmonary fibrosis

One Phase 2 study is in people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and can make breathing harder.^[5] This study is randomized, double-blind, placebo-controlled, and multicenter.^[5] In a double-blind study, neither the participants nor the researchers know who is receiving the study treatment or the placebo during the trial.^[5]

The main outcome in this IPF study is the annualized rate of decline in forced vital capacity (FVC) over 26 weeks.^[5] FVC is a lung test that measures how much air a person can forcefully breathe out after a deep breath.^[5] The study aims to see the effect of Axatilimab compared with placebo on lung function from baseline to Week 26.^[5]

Trial designs and comparison groups

The trials use several common research designs, including randomized, open-label, double-blind, and placebo-controlled methods.^{[1][2][3][5][6]} Randomized means treatment groups are assigned by chance, which helps make the groups more similar at the start.^{[1][2][3][5][6]} Open-label means everyone knows which treatment is being given.^[1][2][6]

The comparison groups include placebo, best available therapy, corticosteroids, and ruxolitinib-based treatment.^{[1][2][3][5][6]} These comparisons help researchers judge whether Axatilimab improves outcomes beyond the current treatment options used in the study.^{[1][2][3][5][6]}

Main outcomes being measured

In cGVHD studies, the main outcome is often overall response, which includes complete response or partial response without needing new systemic therapy by 6 months.^[1][2][4][6] The response is assessed using the 2014 NIH criteria, which are standard rules for measuring disease improvement in cGVHD.^[1][2][4]

In the Phase 3 study of initial cGVHD treatment, the key endpoint is event-free survival.^[3] In the IPF study, the key endpoint is the yearly rate of decline in FVC over 26 weeks.^[5] These endpoints help show whether the study treatment changes the course of the disease in a meaningful way.^[3][5]

Who may be able to participate

The trial data show several target groups, but eligibility differs by study.^{[1][2][3][4][5][6]} Some studies are for adults with cGVHD after at least 2 prior lines of systemic therapy.^[1][4][6] One study is for newly diagnosed cGVHD, and another is for moderate or severe cGVHD as initial treatment.^[2][3]

One trial is specifically for pediatric participants with cGVHD after at least 2 prior lines of systemic therapy.^[6] Another study includes subjects with idiopathic pulmonary fibrosis.^[5] The trial records provided here do not give full eligibility rules, so the exact entry criteria can differ from one study to another.^{[1][2][3][4][5][6]}